In a recent commentary, Victor Fuchs, known as the dean of health economics, explains how health insurance linked to employment skews health care costs
If physicians follow the guidelines for patients with leg and lower back pain and wait before getting MRIs, it could save half a billion dollars a year.
A Stanford study has found that mandated public disclosure of physicians' financial ties may have diminished trust in all physicians.
Health spending in the U.S. is projected to accelerate in the next decade. Stanford professor Kevin Schulman offers an explanation.
Retail prices at pharmacies may bear little relationship to the actual market prices of medications, and pharmacy benefit managers are part of the reason.
Rhode Island has instituted cost controls to limit the growth in health care spending. A Stanford analysis suggests they are effective.
Proponents say a "Medicare for All" approach would expand access and affordability of health care in the U.S. But there are practical downsides.
The cost of treating animal-related injuries in U.S. emergency rooms is about $1.2 billion per year, a new Stanford study shows.
Access and cost of insulin is affecting those who need it most, and without major improvements, millions will be without a treatment, a new study suggests.
Including price information in TV advertisements may lead consumers to avoid care or may misrepresent the actual cost of care, a Stanford scholar writes.
A Stanford professor unpacks some of the dynamics of the current drug pricing system and the potential effects of other approaches to this market.
A Stanford-led study examines whether the Patient Activation Measure can serve as an early indicator that an effort is affecting health care costs
Targeted screening can cut hepatitis B related deaths in the U.S. by half - and save money.
A diabetes program, developed with a Stanford scientist, helps cut costs of diabetes-related health care expenses by $815 per year per person.
It’s one of the hardest questions in medicine: Should hospitals ever stop spending money to avert certain preventable deaths?
Stanford's David Ouyang sifted through more than a million texts to find out if clinicians inadvertently endorse brand-name medications over less expensive generic alternatives.
